Skip to main content
OpenTrials
Completed

NCT Number: NCT01371968

Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

This study aims to determine the optimal dose of alfentanil in suppressing the airway reflexes during supreme LMA removal in anaesthetized adult.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–49 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Malaya Medical Centre

Kuala Lumpur, 59100, Malaysia

About this study

The removal of LMA may be associated with coughing, biting, agitation and airway complication such as laryngospasm. Thus it is advisable to remove the LMA when the patient is breathing spontaneously and when the airway reflexes are still depressed. A number of techniques have been used to prevent this adverse emergence phenomenon, such as removing the tube while the patient is in deep plane of anaesthesia or administration of local anaesthetic and intravenous opioids

The administration of intravenous opioids before emergence may be useful for preventing cough, agitation and hemodynamic response. Alfentanyl is proven to suppress cough and agitation during the endotracheal tube emergence. However, its use in suppressing cough in LMA patient has not been evaluated.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ASA I and II patients
  • Age 18 to 49 years old
  • Minor elective day care surgery (> 20 minute and less than 2 hours) which require local anaesthetic infiltration and does not require use of long acting opioids.

Exclusion criteria

  • Potential difficult airway
  • Reactive airway disease or sign and symptoms of upper respiratory tract infection.
  • History of cardiac, pulmonary and renal diseases
  • Body Mass Index > 30 kgm2.
  • Risk of aspiration.
  • Poor dentition with high risk of damage.
  • Patient refusal.

Treatment and study plan

alfentanil

Drug

Alfentanil is administered intravenously at the end of surgery.

Other names: Rapifen

Primary outcomes

  1. Optimal dose of alfentanil for successful LMA removal in spontaneously breathing anaesthetized adults

    Time frame: 6 months

Secondary outcomes

  1. Number of patient with airway complication

    Time frame: after administration of alfentanil and within 1 min of LMA removal

Sponsors and collaborators

Lead sponsor

University of Malaya

Other

Collaborators

  • Malaysian Society of Anaesthesiologists

Registry information

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Jun 13, 2011
Registry last updated
Oct 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.